Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist

International Immunopharmacology

Volumn 17, Issue 2, 2013, Pages 178-183

  Seiberling, Michael ^a   Kamtchoua, Thierry ^a   Stryszak, Paul ^b   Ma, Xuewen ^b   Langdon, Ronald B ^b   Khalilieh, Sauzanne ^b  

^a Covance Clinical Research Unit AG ^*  (Switzerland)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adaptive immunity; Cell mediated immunity; CXCR2 antagonist; Vaccination

Indexed keywords

B LYMPHOCYTE ANTIBODY; FUNGUS ANTIGEN; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; IMMUNOGLOBULIN G; NAVARIXIN; PLACEBO;

ADAPTIVE IMMUNITY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANDIDA ALBICANS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NEUTROPENIA; NEUTROPHIL COUNT; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SEROCONVERSION; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; VACCINATION;

ADAPTIVE IMMUNITY; CELL-MEDIATED IMMUNITY; CXCR2 ANTAGONIST; VACCINATION;

ADULT; AGED; ANTIBODY FORMATION; BENZAMIDES; CELL COUNT; CELLS, CULTURED; CYCLOBUTANES; FEMALE; HEPATITIS A ANTIBODIES; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, INTERLEUKIN-8B; VACCINATION;

EID: 84881521258     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.05.029     Document Type: Article

References (35)

1. Stanescu D, Sanna A, Veriter C, Kostianev S, Calcagni PG, Fabbri LM, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996;51:267-71. (Pubitemid 26086470)
2. Stockley RA. Neutrophils and the pathogenesis of COPD.Chest 2002;121:151S-5S [Suppl.]. (Pubitemid 34497333)
3. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 2009;4:435-59.
4. Gernez Y, Tirouvanziam R, Chanez P. Neutrophils in chronic inflammatory airway diseases: can we target them and how? Eur Respir J 2010;35:467-9.
5. Noguera A, Batle S, Miralles C, Iglesias J, Busquets X, MacNee W, et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 2001;56:432-7. (Pubitemid 32521359)
6. Kim S, Nadel JA. Role of neutrophils in mucus hypersecretion in COPD and implications for therapy. Treat Respir Med 2004;3:147-59. (Pubitemid 39004400)
7. Simpson JL, Phipps S, Gibson PG. Inflammatory mechanisms and treatment of obstructive airway diseases with neutrophilic bronchitis. Pharmacol Ther 2009;124:86-95.
8. Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009;121:55-68.
9. Stadtmann A, Zarbock A. CXCR2: from bench to bedside. Front Immunol 2012;3:263.
10. Thatcher TH, McHugh NA, Egan RW, Chapman RW, Hey JA, Turner CK, et al. Role of CXCR2 in cigarette smoke-induced lung inflammation. Am J Physiol Lung Cell Mol Physiol 2005;289:L322-8. (Pubitemid 41008916)
11. Dwyer MP, Yu Y, Chao J, Aki C, Chao J, Biju P, et al. Discovery of 2-hydroxy-N, N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4- dioxocyclobut-1- enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist. J Med Chem 2006;49:7603-6. (Pubitemid 46033652)
12. Chapman RW, Minnicozzi M, Celly CS, Phillips JE, Kung TT, Hipkin RW, et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 2007;322:486-93. (Pubitemid 47105794)
13. Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J, et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther 2007;322:477-85. (Pubitemid 47105793)
14. Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni P, et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010;35:564-70.
15. Jones SA, Wolf M, Qin S, Mackay CR, Baggiolini M. Different functions for the interleukin 8 receptors (IL-8R) of human neutrophil leukocytes: NADPH oxidase and phospholipase D are activated through IL-8R1 but not IL-8R2. Proc Natl Acad Sci U S A 1996;93:6682-6. (Pubitemid 26230369)
16. Khalilieh S, TsaiM, de Vries D, KraanM. Rising single-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CXCR2, in healthy volunteers [abstract].Eur Respir J 2007;30:613s [(suppl), http://www.ersnet.org/ learning-resources-player/abstract-print-07/main-frameset.htm, accessed 2013-Apr-18].
17. Eash KJ, Greenbaum AM, Gopalan PK, Link DC. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J Clin Invest 2010;120: 2423-31.
18. Lazaar AL, Sweeney LE, MacDonald AJ, Alexis NE, Chen C, Tal-Singer R. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol 2011;72: 282-93.
19. Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O'Byrne PM, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 2012;42: 1097-103.
20. Murphy PM, Baggiolini M, Charo IF, Hébert CA, Horuk R, Matsushima K, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52:145-76. (Pubitemid 30127598)
21. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-21. (Pubitemid 43209108)
22. Semple BD, Kossmann T, Morganti-Kossmann MC. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J Cereb Blood Flow Metab 2010;30:459-73.
23. Fiore AE, Wasley A. Bell BP for the Advisory Committee on Immunization Practices (ACIP). Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-7):1-23.
24. HAVAB 2.0 package insert. Available at: http://www.ilexmedical.com/files/ PDF/ HAVAB-QUNT-AXSpdf.pdf . [accessed 2012-Oct-04].
25. Neilsen GA, Bodsworth NJ, Watts N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men. J Infect Dis 1997;176:1064-7. (Pubitemid 27411052)
26. Chen XQ, Bülbül M, de Gast GC, van Loon AM, Nalin DR, van Hattum J. Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults. J Hepatol 1997;26:260-4. (Pubitemid 27077422)
27. Richtmann R, Chaves RL, Mendonça JS, Konichi SR, Mitre HP, Takei K, et al. Immunogenicity and efficacy of a killed hepatitis A vaccine in day care center children. J Med Virol 1996;48:147-50. (Pubitemid 26063467)
28. DeFranco AL, Locksley RM, Robertson M. Immunity: the immune response in infectious and inflammatory disease. Corby, Northants, UK: Oxford University Press; 2007 172.
29. Dancey JT, Deubelbeiss KA, Harker LA, Finch CA. Neutrophil kinetics in man. J Clin Invest 1976;58:705-15.
30. von Vietinghoff S, Ley K. Homeostatic regulation of blood neutrophil counts. J Immunol 2008;181:5183-8.
31. Andrès E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol 2008;15:15-21. (Pubitemid 350191024)
32. Dale DC. Advances in the treatment of neutropenia. Curr Opin Support Palliat Care 2009;3:207-12.
33. Finley RS, LaCivita CL, Lindley CM. Adverse effects of chemotherapy. In: Adverse Effects of Chemotherapy (Applied Therapeutics, The clinical use of drugs, 6th edition, Young LY, MA Koda-Kimble, eds.), 1995;91-1 to 91-28.
34. Friberg LE, Henningsson A,MaasH, Nguyen L, KarlssonMO. Model of chemotherapyinduced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002;20:4713-21. (Pubitemid 36025290)
35. Hansson EK, Friberg LE. The shape of themyelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia. Cancer Chemother Pharmacol 2012;69:881-90.